{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:48:20Z","timestamp":1788922100706,"version":"build-2803163510"},"reference-count":52,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,3,19]]},"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a rare but serious side effect of bisphosphonates (BPs). Since this disease has no independent code in either of the diseases\u2019 or in the medical procedures\u2019 classifications, it is hard to estimate how many BP patients are affected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective observational epidemiological registry-based study was carried out, using the data of the national service of Hungary on the incidence of BRONJ and related factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>A data analysis was performed, which is relevant for the whole Hungarian population from 2010 to 2014. The socioeconomic and medication data of 236\u2009207 BP patients were analysed, and a method was worked out to define BRONJ patients from the Hungarian BP population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The incidences of BRONJ were analysed according to genders and the types of the BP drugs administered. The marginal interdependence between the types of BP drugs, modes of administration and main indication was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>340 BP patients (0.1%) developed BRONJ. The incidence of BRONJ in Hungary in the malignant indication of BPs is 0.9%, and 0.1% in the non-malignant indication, and the OR to develop BRONJ was OR=9.7 (95% CI 7.8 to 12.1) between them. Although more women developed BRONJ, the proportion of men was significantly higher than that of women. Steroids increase the risk of jaw osteonecrosis, and differences were also found between the BP drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Oncology indicated, intravenously administered and steroid comedicated BP therapies pose a high risk of developing BRONJ in the Hungarian population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-025600","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T08:44:32Z","timestamp":1558601072000},"page":"e025600","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients"],"prefix":"10.1136","volume":"9","author":[{"given":"Edit","family":"Veszelyn\u00e9 Kot\u00e1n","sequence":"first","affiliation":[{"name":"University Pharmacy Department of Pharmacy Administration, Semmelweis Egyetem Gyogyszeresztudomanyi Kar, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00edmea","family":"Bartha-Lieb","sequence":"additional","affiliation":[{"name":"Department of Information Technology, Allami Egeszsegugyi Ellato Kozpont, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Parisek","sequence":"additional","affiliation":[{"name":"Department of Information Technology, Allami Egeszsegugyi Ellato Kozpont, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attil\u00e1n\u00e9","family":"Mesk\u00f3","sequence":"additional","affiliation":[{"name":"University Pharmacy Department of Pharmacy Administration, Semmelweis Egyetem Gyogyszeresztudomanyi Kar, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mih\u00e1ly","family":"Vaszilk\u00f3","sequence":"additional","affiliation":[{"name":"Department of Oro-Maxillofacial Surgery and Stomatology, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Hank\u00f3","sequence":"additional","affiliation":[{"name":"University Pharmacy Department of Pharmacy Administration, Semmelweis Egyetem Gyogyszeresztudomanyi Kar, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"2025121407022031000_9.5.e025600.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"2025121407022031000_9.5.e025600.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2004.02.004"},{"key":"2025121407022031000_9.5.e025600.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2006.11.003"},{"key":"2025121407022031000_9.5.e025600.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(08)01667-4"},{"key":"2025121407022031000_9.5.e025600.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2014.04.031"},{"key":"2025121407022031000_9.5.e025600.6","unstructured":"Gyires K , Zs F . Farmakol\u00f3gia Medicina, 2007."},{"key":"2025121407022031000_9.5.e025600.7","first-page":"5","volume-title":"Osteonecrosis of the jaws: Real and unreal scares LAM KID","volume":"1","author":"Vaszilk\u00f3","year":"2011"},{"key":"2025121407022031000_9.5.e025600.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.9584"},{"key":"2025121407022031000_9.5.e025600.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.03.050"},{"key":"2025121407022031000_9.5.e025600.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"2025121407022031000_9.5.e025600.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2012.06.020"},{"key":"2025121407022031000_9.5.e025600.12","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"2025121407022031000_9.5.e025600.13","unstructured":"Medicines and Healthcare products Regulatory Agency: Bevacizumab and Sunitinib: risk of osteonecrosis of the jaw. Drug Safety Update. 2011;4. https:\/\/www.gov.uk\/drug-safety-update\/bevacizumab-and-sunitinib-risk-of-osteonecrosis-of-the-jaw"},{"key":"2025121407022031000_9.5.e025600.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0866-3"},{"key":"2025121407022031000_9.5.e025600.15","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.385"},{"key":"2025121407022031000_9.5.e025600.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2013.03.019"},{"key":"2025121407022031000_9.5.e025600.17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr435"},{"key":"2025121407022031000_9.5.e025600.18","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jcms.2014.08.002","article-title":"Potential significance of antiestrogen therapy in the development of bisphosphonate related osteonecrosis of the jaw","volume":"42","author":"Vaszilko","year":"2014","journal-title":"J Craniomaxillofac Surg"},{"key":"2025121407022031000_9.5.e025600.19","unstructured":"Veszelyn\u00e9 KE , \u00c1 M . Therapeutic practice of bisphosphonate use and related pharmaceutical issues I-II Acta Pharmaceutica Hungarica. 2016;86:13\u201322."},{"key":"2025121407022031000_9.5.e025600.20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.60.063007.134350"},{"key":"2025121407022031000_9.5.e025600.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068157"},{"key":"2025121407022031000_9.5.e025600.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2007.11.012"},{"key":"2025121407022031000_9.5.e025600.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2006.10.061"},{"key":"2025121407022031000_9.5.e025600.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067312"},{"key":"2025121407022031000_9.5.e025600.25","first-page":"691","article-title":"Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study","volume":"35","author":"Etminan","year":"2008","journal-title":"J Rheumatol"},{"key":"2025121407022031000_9.5.e025600.26","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2008.0016"},{"key":"2025121407022031000_9.5.e025600.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62051-X"},{"key":"2025121407022031000_9.5.e025600.28","doi-asserted-by":"publisher","DOI":"10.1080\/07357900802208608"},{"key":"2025121407022031000_9.5.e025600.29","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080205"},{"key":"2025121407022031000_9.5.e025600.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200507073530120"},{"key":"2025121407022031000_9.5.e025600.31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8670"},{"key":"2025121407022031000_9.5.e025600.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06230.x"},{"key":"2025121407022031000_9.5.e025600.33","doi-asserted-by":"publisher","DOI":"10.1177\/0022034510397196"},{"key":"2025121407022031000_9.5.e025600.34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-Based Review of Osteonecrosis of the Jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J Clin Densitom"},{"key":"2025121407022031000_9.5.e025600.35","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0707onj"},{"key":"2025121407022031000_9.5.e025600.36","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2405"},{"key":"2025121407022031000_9.5.e025600.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100221"},{"key":"2025121407022031000_9.5.e025600.38","unstructured":"Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. United States. Food and Drug Administration. 2011. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/ CommitteesMeetingMaterials\/drugs\/DrugSafetyandRiskManagementAdvisoryCommittee\/ucm270958.pdf (Accessed 10 Feb 2014)."},{"key":"2025121407022031000_9.5.e025600.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2013.06.221"},{"key":"2025121407022031000_9.5.e025600.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp043801"},{"key":"2025121407022031000_9.5.e025600.41","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02851.x"},{"key":"2025121407022031000_9.5.e025600.42","doi-asserted-by":"crossref","unstructured":"Lakatos P , T\u00f3th E , Zs L , et al . Adherence of Hungarian postmenopausal women with osteoporosis LAM KID. 2012;2:5\u201315.","DOI":"10.1016\/j.jval.2012.08.1411"},{"key":"2025121407022031000_9.5.e025600.43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1097-8690(08)70842-4","article-title":"Jaw necrosis affects 1 in 1,700 on oral bisphosphonates","volume":"41","author":"Ault","year":"2008","journal-title":"Internal Medicine News"},{"key":"2025121407022031000_9.5.e025600.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-1024-9"},{"key":"2025121407022031000_9.5.e025600.45","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025121407022031000_9.5.e025600.46","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0115"},{"key":"2025121407022031000_9.5.e025600.47","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2008.0017"},{"key":"2025121407022031000_9.5.e025600.48","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.4.491"},{"key":"2025121407022031000_9.5.e025600.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.01.047"},{"key":"2025121407022031000_9.5.e025600.50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05771.x"},{"key":"2025121407022031000_9.5.e025600.51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm370"},{"key":"2025121407022031000_9.5.e025600.52","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.joms.2009.12.030","article-title":"Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw--a serial case analysis","volume":"68","author":"Chiu","year":"2010","journal-title":"J Oral Maxillofac Surg"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-025600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:02:29Z","timestamp":1765724549000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-025600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,22]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1136\/bmjopen-2018-025600"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-025600","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}